Speaker Profile

Ph.D., Professor, UCSF

Biography
Dr. Lynch’s research focuses primarily on the gut and airway microbiome and chronic inflammatory disease. She received her undergraduate and graduate degrees in Microbiology from University College Dublin, Ireland, before postdoctoral training as a Dean’s Fellow in the Department of Microbiology and Immunology at Stanford University. She has served on a National Academy of Science and Engineering committee and as an American Society of Microbiology, Distinguished Lecturer (2017-2019). She was awarded the Rebecca Buckley Lectureship from the AAAAI in 2015, the Odell lectureship from University of Wisconsin in 2022 and named as one of Foreign Policy Magazine’s "Global Thinkers" in 2016. She co-founded Siolta Therapeutics Inc. a biotech company whose lead live biotherapeutic for the prevention of childhood atopy and asthma is in human trials.

Talk
Infant Gut Microbiomes as Predictors of Childhood Disease
Gut microbiomes develop like most new ecosystems, via a process of primary succession. Thus understanding early life events and microbial seeding patterns that shape immune maturation offers the opportunity to predict and perhaps prevent childhood diseases.


 Session Abstract – PMWC 2022 Silicon Valley


Track Chair:
Rita Colwell, Johns Hopkins Bloomberg School of Public Health
Manoj Dadlani, CosmosID

Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the Microbiome field and panel discussions on the challenges for faster adoption.

    Sessions:
  • Intro and Overview to Microbiome
    - Manoj Dadlani, CosmosID
  • Regulatory Perspective
    - Scott Jackson, NIST
  • Metabolomics in Drug Development
    - Rangaprasad Sarangarajan, Metabolon
  • Pharma Drug Development (PANEL)
    Session Chair: Karim Dabbagh, Second Genome
    - Jennifer Wortman, Seres Therapeutics
    - Paul Garofolo, Locus Biosciences
    - Rangaprasad Sarangarajan, Metabolon
  • AI in Microbiome
    - Agnieszka Piotrowska, Ardigen
  • Direct-To-Consumer Testing/Technologies (PANEL)
    Session Chair: Nathan D. Price, Thorne HealthTech
    - Kiran Krishnan, Microbiome Labs
    - Nicole Scott, Cybele Microbiome
  • The Role of the Human Gut Microbiome on Various Diseases
    - Colleen Cutcliffe, Pendulum Therapeutics
    - Tor Savidge, Baylor College of Medicine
    - Nikole Kimes, Siolta Therapeutics
    - Susan Lynch, UCSF
  • The Gut/Brain Microbiome
    - Mary Conrad, Axial Biotherapeutics
    - Christopher Reyes, Bloom Science
  • Showcase
    - Heloise Breton, DNA Genotek
    - Nathan Price, Thorne HealthTech
    - Manoj Dadlani, CosmosID